Novel Treatments for High-Risk Rectal Adenocarcinoma: Carlos Fernández-Martos, MD

​Carlos Fernández-Martos, MD, and colleagues recently reported that in patients with high-risk, locally advanced rectal adenocarcinoma, adding aflibercept (Zaltrap®, Regeneron Pharmaceuticals, Inc.) to a modified schedule of fluorouracil/leucovorin/oxaliplatin (FOLFOX6) followed by standard chemoradiotherapy and total mesorectal excision surgery increased treatment efficacy, producing a higher complete pathologic response rate. In this interview with i3 Health, Dr. Fernández-Martos discusses the...
Continue reading

Rectal Cancer: Aflibercept Increases Treatment Efficacy

A phase 2 trial reports that in patients with high-risk, locally advanced rectal adenocarcinoma, adding aflibercept (Zaltrap®, Regeneron Pharmaceuticals, Inc.) enhances the efficacy of neoadjuvant chemotherapy that is followed by standard chemoradiotherapy and surgery. By inhibiting vascular endothelial growth factor (VEGF), aflibercept blocks angiogenesis—the formation of new blood vessels—in cancer cells, thereby inhibiting their growth. "Preclinical studies suggest that a VEGF blockade may pl...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.